|
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
SINGAPORE, Nov 01, 2017 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
3F Mosquito, a fragrance made up of specialized oils sourced from botanicals that mosquitoes avoid, has shown 100% repellency against mosquitoes in laboratory testing. Global BioLife contracted U.S-based Snell Scientifics LLC ("Snell") in Meansville, Georgia to conduct the mosquito studies for the mosquito deterring technologies.
In August 2017 SeD announced that Global BioLife was collaborating with U.S-based Chemia Corporation to develop a suite of fragrances for medical applications referred to as 3F (Functional Fragrance Formulation). Global BioLife entered into further collaboration with Chemia to co-develop 3F Mosquito for laundry detergents, shampoos and lotions.
3F Mosquito products are based on extensive research of botanical oils which possess mosquito repelling properties. When 3F is infused into products such as detergents, shampoos, and lotions, consumers will be provided with multiple layers of protection against mosquito bites, a revolutionary alternative to traditional mosquito repellents.
"Chemia is very excited to introduce these sustainable and tested fragrances to provide natural alternatives to protecting consumers from the risk of mosquito transmitted diseases," said Mr. Thomas A. Meyer, Chemia's Vice-President of Innovation and Sustainability.
The uniquely-designed mosquito deterring paints and functional fabric both deter mosquitoes by chemical-free photonic means; a wavelength of light is emitted that mosquitoes avoid. Snell reported that Global BioLife's photonic mosquito paints and mosquito fabric both exhibit degrees of repellency effective against mosquitoes.
Global BioLife and Chemia have designed the mosquito deterring fabric for use in outdoor apparel, hats, tents, and other camping gear. The mosquito deterring paints were designed as exterior paints for homes as well as commercial applications. These new mosquito deterring technologies are non-chemical methods of repelling mosquitoes for consumers. Mr. Daryl Thompson, Global BioLife Director of Scientific Initiatives, said "The objective in the design of 3F Mosquito was to identify and create a suitable formula that was both pleasant and would excel in protective abilities against mosquitoes. These oils are scientifically proven to affect mosquitoes' receptors, essentially making the mosquito blind to your presence. 3F offers a pleasant scent while providing layers of protection to keep people safe from mosquito bites."
The market for safe mosquito repellents and deterrents is growing as the risk of Zika grows. The most vulnerable group of our population at highest risk for Zika infection may be pregnant women, because of their avoidance and dislike of products containing Deet. The US Center for Disease Control has released multiple statements that the use of Deet is safe, however pregnant women continue to be hesitant to use Deet-containing products.
Dr. Peggy Tang, Global BioLife's CEO, commented: "We expect that these new techniques for fighting mosquito bites will be very appealing to consumers. We are providing unique and useful products, free of harsh chemicals. Due to the perceived toxicity of Deet and the avoidance of chemicals by consumers, Global BioLife's chemical-free products will have a direct advantage over traditional mosquito repellents."
"Biomedical science has become increasingly vital. Global BioLife is proud to be taking steps to provide solutions to issues that have been plaguing the biomedical field for decades. This collaboration marks one of the first steps in actively changing the game of healthcare," said SeD and Global BioLife Executive Chairman Mr. Chan Heng Fai.
Mr. Thomas Meyer added: "This groundbreaking partnership with Global BioLife sets the stage for a steady stream of innovative fragrances that feature functional properties in various consumer product applications."
In addition to 3F Mosquito, Global BioLife is working with Chemia on the formulation of additional 3F fragrances to fight stress and anxiety and 3F for anti-viral medical applications.
About Global BioLife Inc.
Global BioLife Inc. ("GBLI") is a 80%-held direct subsidiary of Global BioMedical Inc., which is a wholly-owned direct subsidiary of Singapore BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange. The remaining shareholding of Global BioLife Inc. is held by Global Research and Discovery Group Scientific LLC ("GRDGS") and Australian Exchange-listed Holista CollTech Limited ("Holista") in equal proportions of 10% each.
With an aging population and a growing focus in healthcare issues, biomedical science has become increasingly vital. GBLI strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. GBLI is also collaborating with its partners to develop second generation mosquito defence technologies, which are DEET alternatives, to protect against mosquito transmitted diseases such as Zika and Dengue. For more information, please visit: http://www.globalbiolife.com About Chemia Corporation
Chemia Fragrance and Flavor provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. For more information, please visit: http://www.chemiacorp.com.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.
Source: Alset International Ltd Sectors: BioTech, Healthcare & Pharm, Cosmetics, Spec.Chem
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
Latest Release
 Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma Oct 30, 2025 00:53 JST
|  Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025 Oct 30, 2025 00:33 JST
|  Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 30, 2025 00:26 JST
|  NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI Oct 30, 2025 00:18 JST
|  Overview of Honda CEO Speech at the Japan Mobility Show 2025 Oct 30, 2025 00:00 JST
|  Honda Presents World Premiere of the Prototype of Honda 0 a, new SUV Model for Honda 0 Series at Japan Mobility Show 2025 Oct 29, 2025 23:55 JST
|  Honda Presents World Premiere of Super-ONE Prototype Compact EV at Japan Mobility Show 2025 Oct 29, 2025 23:50 JST
|  Mitsubishi Motors Debuts Mitsubishi Elevance Concept and Adventure-Inspiring Lineup at Japan Mobility Show 2025 Oct 29, 2025 23:39 JST
|  Fujitsu and PwC Japan partner on economic security measures for sovereign cloud solution Oct 29, 2025 23:22 JST
|  Hitachi Rail becomes world's first transportation firm to adopt new NVIDIA IGX Thor solution for real-time AI Oct 29, 2025 23:00 JST
|  Olympus Introduces NBI+TXI(TM) Observation Mode to the EVIS X1(TM) Endoscopy System CV-1500 Video System Center Oct 29, 2025 11:00 JST
|  Gannon & Scott has signed a definitive agreement to join Metalor Technologies Oct 29, 2025 04:00 JST
|  Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma Oct 29, 2025 00:30 JST
|  Mitsubishi Heavy Industries Machinery Systems to Exhibit at Japan Mobility Show 2025 Oct 29, 2025 00:00 JST
|  Fujitsu AI transforms regional healthcare in Iki city Oct 28, 2025 23:24 JST
|  Hitachi announces initiatives aligned with Japan - U.S. strategic investments Oct 28, 2025 22:34 JST
|  NEC Achieves Cisco Gold Provider Status, Strengthening Global Strategic Partnership in the AI era Oct 28, 2025 22:09 JST
|  Honda to Invest in OMC Power, which will Launch Leasing Business for Uninterruptible Power Supply Device in India Oct 27, 2025 21:20 JST
|  Fujitsu, Logistics Knight Japan, and Isuzu Motors launch joint pilot project to build pharmaceutical logistics platform aiming for stable supply Oct 27, 2025 17:31 JST
|  JCB Explores Opportunities to Expand Card Acceptance through Partnership with STC Bank Oct 27, 2025 15:00 JST
|
More Latest Release >>
|